BACKGROUND: The role of human papillomavirus (HPV) on head and neck squamous cell carcinoma (HNSCC) survival in regions with low HPV prevalence is not yet clear. We evaluated the HPV16 infection on survival of HNSCC Brazilian patient series. METHODS: This cohort comprised 1,093 HNSCC cases recruited from 1998 to 2008 in four Brazilian cities and followed up until June 2009. HPV16 antibodies were analyzed by multiplex Luminex assay. In a subset of 398 fresh frozen or paraffin blocks of HNSCC specimens, we analyzed for HPV16 DNA by L1 generic primer polymerase chain reaction. HNSCC survival according to HPV16 antibodies was evaluated through Kaplan-Meier method and Cox regression. RESULTS: Prevalence of HPV16 E6 and E6/E7 antibodies was higher in oropharyngeal cancer than in other head and neck tumor sites. HPV16 DNA positive in tumor tissue was also higher in the oropharynx. Seropositivity for HPV16 E6 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer. The presence of HPV16 E6/E7 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer survival. The death risk of oropharyngeal squamous cell carcinoma patients HPV16 E6/E7 antibodies positive was 78 % lower than to those who test negative. CONCLUSION: Oropharyngeal squamous cell carcinoma is less aggressive in the HPV16 E6/E7 positive serology patients. HPV16 E6/E7 antibody is a clinically sensible surrogate prognostic marker of oropharyngeal squamous cell carcinoma.
BACKGROUND: The role of human papillomavirus (HPV) on head and neck squamous cell carcinoma (HNSCC) survival in regions with low HPV prevalence is not yet clear. We evaluated the HPV16 infection on survival of HNSCC Brazilian patient series. METHODS: This cohort comprised 1,093 HNSCC cases recruited from 1998 to 2008 in four Brazilian cities and followed up until June 2009. HPV16 antibodies were analyzed by multiplex Luminex assay. In a subset of 398 fresh frozen or paraffin blocks of HNSCC specimens, we analyzed for HPV16 DNA by L1 generic primer polymerase chain reaction. HNSCC survival according to HPV16 antibodies was evaluated through Kaplan-Meier method and Cox regression. RESULTS: Prevalence of HPV16 E6 and E6/E7 antibodies was higher in oropharyngeal cancer than in other head and neck tumor sites. HPV16 DNA positive in tumor tissue was also higher in the oropharynx. Seropositivity for HPV16 E6 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer. The presence of HPV16 E6/E7 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer survival. The death risk of oropharyngeal squamous cell carcinomapatientsHPV16 E6/E7 antibodies positive was 78 % lower than to those who test negative. CONCLUSION:Oropharyngeal squamous cell carcinoma is less aggressive in the HPV16 E6/E7 positive serology patients. HPV16 E6/E7 antibody is a clinically sensible surrogate prognostic marker of oropharyngeal squamous cell carcinoma.
Authors: Krystle A Lang Kuhs; Aimée R Kreimer; Sumita Trivedi; Dana Holzinger; Michael Pawlita; Ruth M Pfeiffer; Sandra P Gibson; Nicole C Schmitt; Allan Hildesheim; Tim Waterboer; Robert L Ferris Journal: Cancer Date: 2017-09-26 Impact factor: 6.860
Authors: Franziska Hauck; Michelle Oliveira-Silva; Johannes H Dreyer; Victor José Ferreira Perrusi; Roberto Alfonso Arcuri; Rocio Hassan; Cibele Rodrigues Bonvicino; Mario Henrique M Barros; Gerald Niedobitek Journal: Virchows Arch Date: 2015-03-28 Impact factor: 4.064
Authors: Krystle A Lang Kuhs; Michael Pawlita; Sandra P Gibson; Nicole C Schmitt; Sumita Trivedi; Athanassios Argiris; Aimée R Kreimer; Robert L Ferris; Tim Waterboer Journal: Cancer Epidemiol Date: 2016-03-21 Impact factor: 2.984
Authors: Krystle A Lang Kuhs; C Burton Wood; Jamie Wiggleton; Joseph M Aulino; Brian Latimer; Derek K Smith; Noemi Bender; Sarah Rohde; Kyle Mannion; Young Kim; Robert Sinard; Alexander Langerman; Arthur Fleischer; Carole Fakhry; Tim Waterboer; James L Netterville Journal: Cancer Date: 2020-03-04 Impact factor: 6.860
Authors: Gypsyamber D'Souza; Devasena Anantharaman; Tarik Gheit; Behnoush Abedi-Ardekani; Daniel C Beachler; David I Conway; Andrew F Olshan; Victor Wunsch-Filho; Tatiana N Toporcov; Wolfgang Ahrens; Kathy Wisniewski; Franco Merletti; Stefania Boccia; Eloiza H Tajara; Jose P Zevallos; José Eduardo Levi; Mark C Weissler; Sylvia Wright; Ghislaine Scelo; Angela L Mazul; Massimo Tommasino; Gabriella Cadoni; Paul Brennan Journal: Oral Oncol Date: 2016-09-26 Impact factor: 5.337
Authors: Devasena Anantharaman; Behnoush Abedi-Ardekani; Daniel C Beachler; Tarik Gheit; Andrew F Olshan; Kathy Wisniewski; Victor Wunsch-Filho; Tatiana N Toporcov; Eloiza H Tajara; José Eduardo Levi; Raquel A Moyses; Stefania Boccia; Gabriella Cadoni; Guido Rindi; Wolfgang Ahrens; Franco Merletti; David I Conway; Sylvia Wright; Christine Carreira; Helene Renard; Priscilia Chopard; Sandrine McKay-Chopin; Ghislaine Scelo; Massimo Tommasino; Paul Brennan; Gypsyamber D'Souza Journal: Int J Cancer Date: 2017-02-14 Impact factor: 7.396
Authors: Chrystiano de C Ferreira; Rozany Dufloth; Ana C de Carvalho; Rui M Reis; Iara Santana; Raiany S Carvalho; Ricardo R Gama Journal: PLoS One Date: 2021-06-17 Impact factor: 3.240